GlassScriptPhysician profile
Peter A Nassar
NPI 1629157243
$140,734.08
in general payments reported to CMS, 2019-2025
18 companies · $61K in 2025
The $61K reported for 2025 was more than what 98% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $688 · 2021: $11K · 2022: $13K · 2023: $18K · 2024: $37K · 2025: $61K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $95K · Travel and Lodging: $14K · Food and Beverage: $5,906 · Education: $304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $95,370.00 |
| Travel and Lodging | $14,138.84 |
| Food and Beverage | $5,905.97 |
| Education | $304.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $114,213.91 | 2019-2025 | |
| Inspire Medical Systems, INC. | $23,779.36 | 2020-2025 | Inspire |
| Harmony Biosciences LLC | $631.17 | 2020-2025 | Wakix |
| Avadel Cns Pharmaceuticals, LLC | $476.40 | 2023-2025 | Lumryz |
| Axsome Therapeutics, INC. | $410.68 | 2022-2025 | Sunosi |
| Eisai INC. | $192.64 | 2020-2021 | |
| Fisher & Paykel Healthcare INC | $170.37 | 2019-2025 | Fisher & Paykel Healthcare |
| Idorsia Pharmaceuticals US INC | $155.32 | 2022-2024 | Quviviq |
| Itamar Medical INC | $127.11 | 2023-2024 | Watchpatone |
| Novo Nordisk INC | $120.87 | 2024 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $120.19 | 2022 | |
| Amgen INC. | $109.14 | 2020 | |
| Merck Sharp & Dohme LLC | $68.96 | 2022-2023 | Belsomra |
| Lilly USA, LLC | $63.71 | 2025 | Zepbound, Mounjaro |
| Philips North America LLC | $32.09 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $28.83 | 2022 | |
| Resmed Corp | $20.25 | 2022 | |
| Aytu Biopharma, INC. | $13.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Nassar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.